Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02398461 · ClinicalTrials.gov registry record · Phase 1
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
A Phase 1 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02398461 is a Phase 1 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT02398461, a Phase 1 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a Phase 1, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study in subjects with relapsing Multiple Sclerosis (MS). The primary outcome will be the safety and tolerability of a single dose of rHIgM22 in relapsing MS subjects.
Interventions
- DRUG Placebo
- DRUG rHIgM22
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02398461
The ClinicalTrials.gov registry entry for NCT02398461 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02398461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02398461 about?
NCT02398461 is a clinical study titled "An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse". This is a Phase 1, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study in subjects with relapsing Multiple Sclerosis (MS). The primary outcome will be the safety and tolerability of a single dose of rHIgM22 in relapsing MS subjects.
What is the current status of trial NCT02398461?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-04. Estimated completion is 2017-09-21.
What interventions are being tested in trial NCT02398461?
The interventions under investigation include: Placebo (DRUG), rHIgM22 (DRUG).
Who is sponsoring clinical trial NCT02398461?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.